CP-945598 Pages on BioPortfolio:

BioPortfolio - CP-945598
CP-945598 - BioPortfolio. ... Recent Search Terms used to find this page: CP - 945598 RAT ... CP-945598 is a selective antagonist of the cannabinoid. ...
http://www.bioportfolio.com/search/CP-945,598.html...

BioPortfolio - CP-945598 RAT
CP-945598 RAT - BioPortfolio. ... CP-945598 RAT Pages on BioPortfolio: ... Recent Search Terms used to find this page: dry bath | CP-945598 RAT | http://
...
http://www.bioportfolio.com/search/CP-945598_RAT.html...

BioPortfolio - cp
Development of rimonabant and CP-945598 for obesity is discontinued One month after Merck ... Recent Search Terms used to find this page: CP - 945598 RAT .
...
http://www.bioportfolio.com/search/cp.html...

BioPortfolio - CP 866087
18.3.1 CP 945598 and Capromorelin 18.3.2 Axitinib 18.3.3 Ticilimumab 18.3.4 SU 6668 18.3.5 ... which ... http://www.bioportfolio.com/search/CP-945598.html. ...
http://www.bioportfolio.com/search/CP_866087.html...

BioPortfolio - dry bath
Baths - BioPortfolio - Indepth. ... find this page: dry bath | CP-945598 RAT ... Recent Search Terms used to find this page: CP-945598 | portable sitz bath ...
http://www.bioportfolio.com/search/dry_bath.html...

BioPortfolio - portable sitz bath
BioPortfolio - CP-945598 RAT BioPortfolio - portable sitz bath Recent Search ... Recent Search Terms used to find this page: CP-945598 | portable sitz bath ...
http://www.bioportfolio.com/search/portable_sitz_bath.html...

BioPortfolio - United States Patent 7329366
Recent Search Terms used to find this page: CP-945598 | portable sitz bath | United States Patent ... http://www.bioportfolio.com/search/CP-945598.html. ...
http://www.bioportfolio.com/search/United_States_Patent_7329...

BioPortfolio - investigational new drug update contents
7 Nov 2008 ... to terminate its Phase III testing of investigational drug (CP- 945598), ... Pro- Pharmaceuticals to Present Corporate Update at the Rodman .
...
http://www.bioportfolio.com/search/investigational_new_drug_...

BioPortfolio Limited Anti-Obesity Treatments 2007 to 2012 A ...
7.2.2 Pfizer’s CP 945598 7.2.3 Orexigen’s Bupropion and Naltrexone (Contrave) 7.2.4 Arena’s Lorcaserin 7.3 Discussion of Current Pipeline Developments ...
http://www.bioportfolio.com/cgi-bin/acatalog/info_309.html...

BioPortfolio - CP - ceruloplasmin (ferroxidase)
Development of rimonabant and CP-945598 for obesity is discontinued, Formulary Journal: Nov 14 2008 2:54AM Matching: cp ...
http://www.bioportfolio.com/gene/1356-CP.html...

Results from other life science and pharmaceutical sites:

News: Pfizer Discontinues Development Program for Its Phase 3 ...
Pfizer, Inc announced today that it is terminating the phase 3 development program for its investigational compound (CP-945598) for weight management. ...
http://www.genengnews.com/news/bnitem.aspx?name=44888149&chi...

Patent alert
chemical structure of CP-945598. This process patent. provides strong evidence for the ... specified compounds in this patent as CP-945598, and also ...
http://www.biomedcentral.com/content/pdf/cd-769592.pdf...

Advances in Neurohormonal Therapy in the Treatment of Obesity ...
The CB1 receptor antagonists, of which there are three in development, CP945598, taranabant, and rimonabant which I will show you. ...
http://www.medscape.com/viewarticle/569296...

News: Pfizer Pulls the Plug on Late-Stage Obesity Treatment ...
6 Nov 2008 ... Pfizer decided to ax Phase III development of its weight-management compound, CP -945598, a selective antagonist of the cannabinoid type 1 ...
http://www.genengnews.com/news/bnitem.aspx?name=44937715&nc=...

Pharmacotherapeutic Approaches to the Clinical Management of ...
CP 945598 is in phase 3 trials, and there are several other compounds also in .... Finally, there is CP 945598, which is now undergoing a 2-year, ...
http://www.medscape.com/viewarticle/573694...

Boston Medical Center
A 14 month, randomized, double blind, placebo controlled phase 3 study to evaluate the long term efficacy and safety of CP 945598 in prevention of weight
...
http://www.bmc.org/medicine/medicine/nutrition/research.html...

News: Pfizer Pulls the Plug on Late-Stage Obesity Treatment ...
Pfizer decided to ax Phase III development of its weight-management compound, CP -945598, a selective antagonist of the cannabinoid type 1 (CB1) receptor. ...
http://www.genengnews.com/news/bnitem.aspx?name=44937715...

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.